SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Scilex entered into a binding term sheet on June 24, 2026 to purchase 837 BTC from Datavault for $50 million, with an initial $30 million payment and remaining $20 million in quarterly installments through 2028, contingent on execution of a definitive agreement and satisfaction of closing conditions.
View raw filing on EDGAR →Scilex contemplates an unregistered private placement of Company Common Stock to Datavault, an accredited investor, in a transaction exempt under Section 4(a)(2) and Regulation D Rule 506, as part of the proposed Bitcoin acquisition transaction.
View raw filing on EDGAR →The primary disclosure is the announcement of a preliminary proxy statement for a special shareholder meeting to vote on a share consolidation (1:5 to 1:20 ratio) intended to position TerrAscend for uplisting to a major U.S. stock exchange. While the filing also includes a segment presentation recast (New Jersey, Maryland, Pennsylvania), the salient event is the shareholder vote on the share consolidation, which is a governance matter. The consolidation is material to investors as it directly affects share structure and is a prerequisite for the company's stated uplisting strategy.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of the 2026 Annual Meeting of Stockholders held on June 25, 2026. The filing presents voting results for two proposals: (1) election of Class III Directors (R. Nolan Townsend, Brenda Cooperstone, and Paula HJ Cholmondeley) and (2) ratification of KPMG LLP as the independent auditor. The tabulated vote counts (FOR, WITHHELD/AGAINST, BROKER NON-VOTE/ABSTAIN) are the hallmark of shareholder vote result disclosures.
View raw filing on EDGAR →Andersen Group Inc. entered into a $50 million asset-based revolving credit facility with JPMorgan Chase Bank on June 25, 2026. This is a material creation of a new direct financial obligation—a credit agreement establishing a revolving credit facility with specified terms, interest rates (Term SOFR + 175 bps), covenants, and collateral requirements. The facility is secured by first lien on all assets of the Loan Parties and includes guarantees from multiple subsidiaries, making it a significant financing event material to investors.
View raw filing on EDGAR →This is a press release announcing topline results from ABTECT Maintenance Part 2, a Phase 3 clinical trial of obefazimod for ulcerative colitis. The disclosure reports efficacy and safety data from a material clinical milestone—specifically, positive results in a refractory patient population and expanded safety database—that would affect a reasonable investor's assessment of the company's lead drug candidate and regulatory pathway. The company explicitly states it remains "on track to submit its NDA to the U.S. Food and Drug Administration in the fourth quarter of 2026," making these trial results directly relevant to near-term value drivers. While this is not a financial earnings release in the traditional sense, it is a material clinical results announcement that functions as a discrete event disclosure of significant business importance.
View raw filing on EDGAR →Karen Grimes, Marcos Lutz, Charles Magro, and Kerry Preete resigned from Corteva's board of directors effective immediately prior to the spin-off consummation, representing a significant change in board composition for the parent company in connection with the planned separation.
View raw filing on EDGAR →Corteva announced the post-separation boards of directors for Corteva and Vylor in connection with its planned separation of its seed business into an independent public company, scheduled for 4Q 2026, constituting a material disposition of a business segment.
View raw filing on EDGAR →Digital Realty entered into an agreement to acquire Blackstone's 64% equity interests in two Northern Virginia data center joint ventures (Digital Carver Dulles 9 and Digital Carver Brickyard) for $3.5 billion in total consideration ($1.231 billion cash and $2.346 billion in non-voting common stock), resulting in wholly owned subsidiaries controlling 288 megawatts across three hyperscale facilities valued at $7.8 billion gross.
View raw filing on EDGAR →Contango Silver & Gold entered into a First Amendment to the Membership Interest Purchase and Sale Agreement on June 26, 2026, settling $18.75 million in milestone payment obligations for $5 million cash and 100,000 common shares. This amendment eliminates remaining contingent liabilities and encumbrances on the Lucky Shot Project, securing 100% unencumbered control of the asset and materially modifying the Company's ownership and financial position.
View raw filing on EDGAR →The filing discloses an unregistered sale of 560,488.164 shares of Class I common stock for approximately $8.0 million, exempt under Section 4(a)(2) of the Securities Act and Regulation D. This is a classic dilutive equity issuance by a BDC raising capital through a private placement, which materially affects existing shareholders' ownership percentages and is a significant capital event for the registrant.
View raw filing on EDGAR →IMMUNIC held its annual stockholder meeting and disclosed final voting results, including election of three Class III Directors (Michael Bonney, Thorvald Nagel, and Richard Rudick), approval of an amendment to the 2019 Omnibus Equity Incentive Plan increasing authorized shares by 6,000,000, and ratification of Baker Tilly as independent auditor.
View raw filing on EDGAR →Star Equity Holdings announced its inclusion in the Russell Microcap Index following the 2026 reconstitution, effective June 26, 2026. While this is a positive operational/strategic milestone that increases institutional visibility and investor awareness, it does not fit neatly into any specific event category. The company characterizes it as "a meaningful milestone" that "expands our visibility within the institutional investment community." This is a material operational event reflecting market recognition and improved access to capital markets, but it is not a governance matter, financial obligation, M&A activity, or other named event type.
View raw filing on EDGAR →The filing discloses that T1 Energy's publicly traded warrants will expire on July 9, 2026, cease trading on the NYSE under symbol "TE WS" before market open that day, and the NYSE intends to file a Form 25 with the SEC to effect delisting and deregistration of the Public Warrants under Section 12(b) of the Securities Exchange Act. This is a material delisting event affecting the warrant securities, though the Common Stock will continue trading under "TE."
View raw filing on EDGAR →The Company issued 1,310,969 shares of common stock to ASPIS Cyber Technologies for $1.7 million under a Stock Purchase Agreement dated April 15, 2026, consummated on June 26, 2026. The issuance is explicitly exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, which are hallmarks of a private placement. This unregistered equity issuance is material to investors as it represents significant dilution and capital raising activity.
View raw filing on EDGAR →The 6-K discloses the Second Closing on June 25, 2026, whereby Kandal M Venture Limited issued a $1,000,000 senior unsecured convertible promissory note bearing 10% interest, maturing June 5, 2029, and convertible into Class A Ordinary Shares. This is a material creation of a direct financial obligation under a securities purchase agreement with an institutional investor, fitting the debt_issuance category. The convertible feature and registration rights agreement are ancillary to the core debt issuance event.
View raw filing on EDGAR →This press release announces the closing of a registered direct offering of 400,000 ADSs at $10.00 per ADS (a 10.7% premium to market) plus warrants to purchase 300,000 additional ADSs, raising $4.0 million gross proceeds. The offering was made pursuant to an effective Form F-3 shelf registration statement, making it a registered equity issuance. While registered offerings are technically not "unregistered" in the strict sense, this is a dilutive equity issuance that materially increases share count and is the type of capital-raising event that would affect a reasonable investor's assessment of ownership dilution and the company's financial position.
View raw filing on EDGAR →PVH Corp. entered into a new Credit Agreement on June 24, 2026, creating direct financial obligations consisting of a €400 million euro-denominated term loan facility and a US$1.5 billion multicurrency revolving credit facility. The company used proceeds from the new borrowing to repay and terminate its prior credit agreement dated December 9, 2022. This is a material refinancing and debt issuance event that creates new direct financial obligations under Item 2.03.
View raw filing on EDGAR →Bitdeer announced execution of a colocation lease agreement for its Tydal, Norway AI data center site through its subsidiary Tydal Data Center AS. This is a material operational/strategic event involving infrastructure expansion for the company's core AI and Bitcoin mining business. While the lease has not yet become effective and remains subject to conditions precedent, the signing of a major data center colocation agreement represents a significant step in the company's global infrastructure strategy and would affect a reasonable investor's assessment of the company's operational capacity and growth trajectory. The event does not fit neatly into predefined categories like `ma_activity` (not an acquisition or merger) or `debt_issuance` (not a financial obligation), making `operational_other` the most appropriate classification for this material strategic infrastructure commitment.
View raw filing on EDGAR →The press release announces the status and progress of a shareholder-approved business combination between Check-Cap Ltd. and MBody AI Corp., which is described as "on track to close in the second half of 2026, subject to customary closing conditions." The disclosure includes material updates on the merger's advancement, including Nasdaq's completion of its initial listing review and the companies' responses to supplemental information requests. While the merger itself was previously disclosed, this exhibit reports a material update on the transaction's progress toward completion, which is a form of M&A activity disclosure.
View raw filing on EDGAR →SandRidge Energy entered into a definitive Purchase and Sale Agreement on June 26, 2026, to acquire oil and gas properties and related assets in the Cherokee Play for $65 million in cash plus up to $6 million in contingent earn-out payments. The acquisition includes approximately 3.0 MBoed production, 7,000 net leasehold acres, and 21 wells, and is characterized as immediately accretive to production, EBITDA, and free cash flow.
View raw filing on EDGAR →This is a press release announcing positive Phase 2b clinical trial results for NeuroSense's lead drug candidate PrimeC in ALS. The disclosure reports achievement of the primary efficacy endpoint (statistically significant TDP-43 reduction, p=0.0421), previously reported clinical outcomes including slowing of disease progression and survival benefit, and advancement toward Phase 3 trials. While not a financial earnings release in the traditional sense, this is a material clinical milestone disclosure that would significantly affect investor assessment of the company's pipeline value and prospects. The language ("achieved primary endpoint," "statistically significant," "compelling body of evidence") and the detailed clinical data presentation mirror the structure and materiality of an earnings-type announcement for a clinical-stage biotech company.
View raw filing on EDGAR →This press release announces Park Ha Biological's strategic partnership with Amazon to enter the North American personal care market, including store qualification, brand registry enrollment, and compliance framework establishment. This is a material operational and strategic business event—a significant market-expansion initiative that would affect a reasonable investor's assessment of the company's growth prospects and international strategy. While it does not fit the specific categories of M&A activity, debt issuance, or workforce reduction, it clearly represents a major operational milestone and strategic partnership that warrants disclosure as a material event.
View raw filing on EDGAR →The exhibit is a shareholder letter dated June 29, 2026, following the Company's Annual General Meeting on June 26, 2026. It explicitly references the AGM vote ("Your vote is not something we take for granted") and reports the Board's mandate and plans to expand independent director representation. While the letter also contains forward-looking strategic commentary, the core disclosure is the AGM outcome and the Board's response, which constitutes shareholder vote results under Item 5.07 equivalent for a foreign private issuer.
View raw filing on EDGAR →Mr. Philip Ling Yan Wong resigned from the Board of Directors and as Co-CEO of Concorde International Group Ltd. effective June 28, 2026. The departure of a Co-CEO and board member is a material executive departure that would affect a reasonable investor's assessment of the company's leadership and governance. The filing explicitly discloses this as a "Departure of Directors or Certain Officers."
View raw filing on EDGAR →The filing discloses the simultaneous dismissal of BCRG as the Company's independent registered public accounting firm and appointment of Simon & Edward LLP as the new auditor, effective June 23, 2026. This is a classic auditor change under Item 4.01. While the disclosure also mentions BCRG's going-concern qualification in prior audit reports, the principal event disclosed is the change in auditors itself, not the going-concern matter (which was previously disclosed). The materiality is high given the change in the registrant's certifying accountant.
View raw filing on EDGAR →This 8-K discloses a Shareholder Q&A document issued following the June 10, 2026 annual meeting. The filing references Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Exhibits), and the Q&A addresses shareholder-approved governance matters including a corporate name change from Triller Group Inc. to Eight Holdings Inc., authorization for a reverse stock split (which was effected on June 25, 2026 at 1-for-10), adoption of a 2026 Equity Incentive Plan, and Nasdaq 20% issuance approval for private placements. While the document contains strategic and operational commentary, the core disclosure event is governance-related—shareholder meeting outcomes and corporate identity/structure changes. The reverse split and name change are material governance actions affecting the registrant's public-company status and shareholder rights.
View raw filing on EDGAR →The press release announces Kandi Technologies' entry into an investment agreement to acquire a 51% controlling stake in Hangzhou Xinchu New Energy Technology Co., Ltd. for RMB20 million (approximately US$2.9 million), with expected close in July 2026. This constitutes a material acquisition and change of control event under Item 1.01 of Form 8-K (or equivalent 6-K disclosure), establishing Kandi's strategic expansion into the AI data center backup power and energy storage market.
View raw filing on EDGAR →The 6-K discloses a proposed private placement of 14,000,000 new ordinary shares at KRW 1,600 per share (total KRW 22.4 billion / HKD 113.6 million) to three subscribers including two individuals and a related entity. This is a dilutive equity issuance requiring shareholder approval at the August 10, 2026 EGM, with proceeds earmarked for working capital (procurement, marketing, R&D). The transaction materially dilutes existing shareholders and raises capital through unregistered equity sales.
View raw filing on EDGAR →The Company received a Nasdaq notification letter on June 26, 2026, stating it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) because the closing bid price was below $1.00 per share for 30 consecutive business days. The Company has 180 calendar days until December 23, 2026, to regain compliance, or it may face delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting the registrant's continued listing status.
View raw filing on EDGAR →Polyrizon announced receipt of central IRB approval from BRANY to begin its first human clinical trial for NASARIX™, an intranasal hydrogel allergy blocker. This is a material regulatory milestone for a development-stage biotech company—it represents significant progress toward commercialization of a lead product candidate and enables advancement to site activation and patient enrollment. While not fitting a discrete named event type, this is clearly an operational/strategic milestone that would affect a reasonable investor's assessment of the company's development trajectory and near-term prospects.
View raw filing on EDGAR →Alpex Acquisition Corp entered into multiple material definitive agreements in connection with its IPO and concurrent private placement, including the Underwriting Agreement, Warrant Agreement, Rights Agreement, and Investment Management Trust Agreement, representing a material capital-raising transaction.
View raw filing on EDGAR →Alpex completed an unregistered private placement of 187,500 Private Units to the Sponsor for $1,875,000 substantially concurrent with the IPO closing, with units subject to transfer restrictions until completion of the initial business combination.
View raw filing on EDGAR →Three independent directors—Yi Hua, Xin Yue Jasmine Geffner, and Yuanmei Ma—were appointed effective June 25, 2026, in connection with the Company's Nasdaq listing and IPO closing, with Geffner designated as audit committee chair and qualified audit committee financial expert.
View raw filing on EDGAR →Alpex Acquisition Corp completed its initial public offering of 11.5 million units raising $115 million in gross proceeds, with concurrent private placement of 187,500 units, representing a material capital-raising transaction for the newly public blank-check SPAC.
View raw filing on EDGAR →The Company issued 500,000 warrants to purchase ordinary shares at $6.25 per share to Taurus Mining Finance on June 29, 2026, pursuant to a waiver letter related to a $60 million senior secured bridge loan facility. This is a dilutive equity issuance tied to debt financing and represents a material capital structure event affecting existing shareholders.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from AleAnna's June 26, 2026 Annual Meeting of Stockholders under Item 5.07. The filing reports the voting outcomes for two proposals: election of Class II directors (Curtis Hébert Jr. and William K. Dirks) and ratification of Deloitte & Touche LLP as independent auditor, with detailed vote tallies showing both proposals were approved. This is a routine but material governance disclosure required by Item 5.07.
View raw filing on EDGAR →The filing discloses results of the 2026 annual meeting of stockholders held on June 29, 2026, with detailed voting tallies for five proposals including director elections, auditor ratification, equity plan amendment, warrant issuance authorization, and reverse stock split approval. Item 5.07 explicitly presents voting results with vote counts for each proposal, which is the defining characteristic of shareholder_vote_results. The equity plan amendment and warrant issuance approvals are material governance and capital structure decisions requiring shareholder authorization.
View raw filing on EDGAR →The Company drew $5,000 thousand under an unsecured promissory note dated January 30, 2024 with Constellation Sponsor LP, creating a direct financial obligation. While this is technically a draw on an existing note rather than a new issuance, it represents the creation of a new financial obligation at the time of drawdown. The funds were deposited into the trust account to extend the business combination deadline, which is material to shareholders evaluating the Company's timeline and sponsor support.
View raw filing on EDGAR →This Item 5.07 filing discloses the results of an extraordinary general meeting of CEPT shareholders held on June 29, 2026, where shareholders voted on four major proposals including approval of a Business Combination Agreement with Securitize, Inc., the CEPT Merger, organizational documents for the post-merger entity (PubCo), and Nasdaq Rule 5635 compliance. All proposals received requisite shareholder approval, with Proposal 1 (Business Combination) receiving 12,432,037 votes for, 2,151,147 against, and 197,157 abstentions. The filing explicitly states that "In light of receipt of the requisite approvals by CEPT Shareholders described above, CEPT expects the Business Combination to be completed promptly," confirming this is a material shareholder vote result that clears the path for a transformative M&A transaction.
View raw filing on EDGAR →Jin Medical International held shareholder meetings (Class A, Class B, and Extraordinary General Meeting) on July 9, 2026, to vote on multiple material proposals including a VIE acquisition, voting-rights changes (Class B voting rights increase from 30 to 800 votes per share), a related-party share repurchase of 3.77M Class A shares from CEO Wang Erqi's entity (Jolly Harmony) at 90-day VWAP, and issuance of 3.77M Class B shares to the same entity, as well as authorized capital increase.
View raw filing on EDGAR →GD Culture Group effected a 1-for-250 reverse stock split of its authorized and issued shares, approved by the Board on June 16, 2026 and effective June 29, 2026, consolidating approximately 1.04 billion shares into approximately 4.16 million shares. The reverse split was previously approved by stockholders on December 31, 2025, and a Certificate of Change was filed with Nevada's Secretary of State on June 18, 2026. This capital structure adjustment affects all shareholders uniformly and impacts the company's trading characteristics on Nasdaq.
View raw filing on EDGAR →The 6-K discloses results of an Extraordinary General Meeting of Shareholders held on June 29, 2026, where shareholders approved four material resolutions: (1) acquisition of 80–100% of Psyga Bio Ltd. via private placement of shares and warrants; (2) private placement of up to $1.5M from specified investors; (3) increase of authorized share capital by 2.9B shares; and (4) appointment of auditors. This is a classic shareholder vote results disclosure under Item 5.07 equivalent, and the underlying transactions (M&A, dilutive issuance, auditor appointment) are material to investors.
View raw filing on EDGAR →Albert Rabil III resigned from the Board of Directors of Kayne DL 2021, Inc., effective immediately on June 29, 2026. The filing explicitly discloses his departure as a Class III director with a remaining term through 2029. While the company confirms the resignation was not due to disagreement, the departure of a board member is a material governance event affecting the composition and independence structure of the board.
View raw filing on EDGAR →Albert Rabil III resigned from the Board of Directors of Kayne Anderson BDC, Inc., effective immediately on June 29, 2026. As a Class III director with a remaining term through 2029, his departure is a material change to the board composition. The filing explicitly confirms the resignation was not due to disagreement, and notes the board composition shifted from seven to six directors with four remaining independent directors.
View raw filing on EDGAR →WISeKey has signed a merger agreement with its wholly owned British Virgin Islands subsidiary to effect a redomiciliation from Switzerland to the BVI. The merger involves a change of control structure where WISeKey merges into WISeKey BVI, with WISeKey BVI surviving as the publicly traded parent company. This is a material acquisition/change of control transaction requiring shareholder approval at an extraordinary general meeting, SEC registration, and Nasdaq/SIX listing authorizations.
View raw filing on EDGAR →Leonardo Viana Nicacio, M.D., the Company's Chief Medical Officer, resigned effective June 26, 2026 to explore other opportunities. This is a clear departure of a named executive officer. While the filing notes that his duties will be assumed by existing personnel (Carla Beckham and oversight by Jacqueline Zummo), the principal disclosed action is the resignation of a C-suite executive, making this an exec_departure event.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from a reconvened annual meeting held on June 23, 2026. The filing reports the outcomes of two proposals: (1) election of Ronald J. Kramer and Leslie D. Michelson as Class III directors, with specific vote tallies (For/Against/Abstain), and (2) stockholder approval to authorize sales of Common Stock below net asset value, with detailed voting results. This directly matches the shareholder_vote_results event type and Item 5.07 disclosure requirement.
View raw filing on EDGAR →Western Uranium & Vanadium held its Annual General and Special Meeting of Shareholders on June 26, 2026, with shareholder approval of director re-elections (George Glasier, Bryan Murphy, Andrew Wilder, Michael Skutezky), reappointment of MNP LLP as auditor, and reapproval of the 2023 Incentive Stock Option Plan and 2023 Shareholder Rights Plan.
View raw filing on EDGAR →The filing discloses the appointment of John P. Sharp as Interim Chief Financial Officer on June 25, 2026, replacing Quang X. Pham. While the section also includes a director resignation (Steven Zelenkofske) and board realignment, the principal disclosed action centers on the CFO appointment, which is material to investors as it affects the company's financial leadership. The detailed biography and compensation terms ($455/hour for up to 24 hours/week under a Master Services Agreement) underscore the significance of this executive appointment.
View raw filing on EDGAR →